News

Under the agreement, Lonza will manufacture material at multiple sites, including Slough (UK), Visp (CH) and Nansha (CN). Retinal diseases, such as age-related macular degeneration (AMD), cause blindness

The parties will work on the part B portion of the MoveDMD clinical trial of CAT-1004. MDA will provide funding required to transport patients who need to travel

The agency sent a complete response letter to Vertex, stating that it cannot approve the company’s supplemental new drug application (sNDA) in its current form. Vertex plans to

Mirvetuximab soravtansine is currently being evaluated in the phase Ib/II FORWARD II study in combination with anticancer agents including Doxil (doxorubicin), Avastin (bevacizumab) and Paraplatin (carboplatin). The mirvetuximab

This is a follow-on investment from the foundation for achievement based on the development of a new pneumococcal vaccine which targets Streptococcus pneumoniae (pneumococcus) towards clinical testing. The

The drug can be taken in combination of sofosbuvir with or without ribavirin in genotypes 1 and 3. With this combination, three difficult to treat patient populations can

The milestone was triggered by Takeda surpassing annual ADCETRIS net sales of $200m in its territory during 2015. The milestone will be recognized as royalty revenue in the

The PDAC recommendation is based on the efficacy results from FOCUS and CONNECT studies, which were specifically designed to evaluate the effect of Brintellix on certain aspects of

This clinical trial is an open label dose-escalation and expansion study designed to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), tolerability, pharmacokinetics and